A Case Report and Literature Review of Antibody Conjugated Drugs for Parotid Ductal Adenocarcinoma
Department of Radiotherapy, Nantong City Tumor Hospital / Nantong University Cancer Hospital, Nantong 226361, China
| Abstract: | Salivary ductal carcinoma (SDC) is a rare highly aggressive malignancy with unique pathological and clinical features, and its histological features are highly similar to that of breast ductal carcinoma. The standard treatment for SDC is surgery plus radiation therapy, but it is often detected late and has a poor prognosis. Human growth factor receptor 2 (HER2) overexpression is common in SDC, and HER2-positive SDC cases have strong aggressiveness, and the standard treatment regimen for patients with postoperative recurrence or metastasis is still controversial. Vedicitumab is an innovative antibody coupling drug independently developed in China. It targets HER2 protein on the tumor surface and can accurately identify and kill tumor cells. This case reports a case of HER2 positive SDC treated with vidiximab alone, which has a rapid onset and significant effect. It may be a promising research direction for the treatment of this disease, but the sample size control study needs to be further expanded. |
| Keywords: | Salivary Duct Carcinoma; Human Growth Factor Receptor 2; Antibody-drug Conjugate; Drug Therapy |
| DOI: | 10.57237/j.cmf.2022.01.004 |
View:
Downloads:
Received: 30 October 2022
Accepted: 1 December 2022
Published Online: 15 December 2022
References
| [1] | Kleinsasser O, Klein HJ, HübnerG. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma [J]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd, 1968, 192 (1): 100-105. |
| [2] | Seifert G, Brocheriou C, Cardesa A, et al. WHO international histological classification of tumours. tentative histological classification of salivary gland tumours [J]. Pathol Res Pract, 1990, 186 (5): 555-581. DOI: 10.1016/S0344-0338(11)80220-7. |
| [3] | Boon E, Bel M, van Boxtel W, et al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands [J]. Int J Cancer, 2018, 143 (4): 758-766. DOI: 10.1002/ijc.31353. Epub 2018 Mar 23. |
| [4] | Airoldi M, Garzaro M, Pedani F, et al. Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases [J]. Am J Clin Oncol, 2017, 40 (1): 86-90. DOI: 10.1097/COC.0000000000000112. |
| [5] | Dalin MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer [J]. Clin Cancer Res, 2016, 22 (18): 4623-4633. DOI: 10.1158/1078-0432.CCR-16-0637. |
| [6] | Chen FJ, Jiang MX, Shao GL. et al. CT imaging findings and clinicopathological features of 16 cases with salivary duct carcinoma in parotid gland [J]. J Chin Oncol, 2015, 21 (5) 436-439. DOI: 10.11735/j.issn.1671-170X.2015.05.B019. |
| [7] | Castellano I, Allia E, Accortanzo V, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers [J]. Breast Cancer Res Treat, 2010, 124 (3): 607-617. DOI: 10.1007/s10549-010-0761-y. |
| [8] | Di Palma S, Simpson RH, Marchiò C, et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes [J]. Histopathology, 2012, 61 (4): 629-643. DOI: 10.1111/j.1365-2559.2012.04252.x. |
| [9] | Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy [J]. Oral Oncol, 2017, 74: 40-48. DOI: 10.1016/j.oraloncology.2017.09.008. |
| [10] | Luk PP, Weston JD, YuB, et al. Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations [J]. Head Neck, 2016, 38 (Suppl 1): E1838-E1847. DOI: 10.1002/hed.24332. |
| [11] | Skálová A, Stenman G, Simpson R, et al. The role of molecular testing in the differential diagnosis of salivary gland carcinomas [J]. Am J SurgPathol, 2018, 42 (2): e11-e27. DOI: 10.1097/PAS.0000000000000980. |
| [12] | JaehneM, RoeserK, JaekelT, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases [J]. Cancer, 2005, 103 (12): 2526-2533. DOI: 10.1002/cncr.21116. |
| [13] | KHONGORZUL P, LING C J, KHAN F U, et al. AntibodyDrug Conjugates: A Comprehensive Review [J]. Mol Cancer Res, 2020, 18 (1): 3-19. |
| [14] | RICCIUTI B, LAMBERTI G, ANDRINI E, et al. Antibodydrug conjugates for lung cancer in the era of personalized oncology [J]. Semin Cancer Biol, 2019, 30:S1044-579X (19): 30424-30429. |
| [15] | Xu Y, Wang Y, Gong J, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021; 24: 913-25. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us